ATE290399T1 - Hbv/hcv virus-ohnliche particle - Google Patents

Hbv/hcv virus-ohnliche particle

Info

Publication number
ATE290399T1
ATE290399T1 AT00982225T AT00982225T ATE290399T1 AT E290399 T1 ATE290399 T1 AT E290399T1 AT 00982225 T AT00982225 T AT 00982225T AT 00982225 T AT00982225 T AT 00982225T AT E290399 T1 ATE290399 T1 AT E290399T1
Authority
AT
Austria
Prior art keywords
virus
particles
hbv
chimeric antigens
hepatitis
Prior art date
Application number
AT00982225T
Other languages
German (de)
English (en)
Inventor
Mark Selby
Edward Glazer
Michael Houghton
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE290399T1 publication Critical patent/ATE290399T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00982225T 1999-11-24 2000-11-22 Hbv/hcv virus-ohnliche particle ATE290399T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16722499P 1999-11-24 1999-11-24
PCT/US2000/032249 WO2001038358A2 (en) 1999-11-24 2000-11-22 Hbv/hcv virus-like particle

Publications (1)

Publication Number Publication Date
ATE290399T1 true ATE290399T1 (de) 2005-03-15

Family

ID=22606465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00982225T ATE290399T1 (de) 1999-11-24 2000-11-22 Hbv/hcv virus-ohnliche particle

Country Status (8)

Country Link
EP (1) EP1233783B9 (enExample)
JP (1) JP4647870B2 (enExample)
AT (1) ATE290399T1 (enExample)
AU (1) AU1928201A (enExample)
CA (1) CA2392527C (enExample)
DE (2) DE60018601D1 (enExample)
ES (1) ES2430368T3 (enExample)
WO (1) WO2001038358A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
EP1476543B1 (en) * 2002-02-07 2014-05-14 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
DE10218129A1 (de) * 2002-04-23 2003-11-20 Univ Ruprecht Karls Heidelberg Genetischer Impfstoff gegen RNA-Virus-Infektionen
US20060240039A1 (en) * 2003-06-13 2006-10-26 Isis Innovation Limited Vaccines
CA2636139A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
EP2530086B1 (en) 2006-06-12 2019-03-20 Kuros Biosciences AG Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
US20080166785A1 (en) * 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
CA2671873C (en) 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides containing high concentrations of guanine monomers
FR2932388B1 (fr) * 2008-06-17 2013-03-29 Univ Rabelais Francois Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
JP2014212722A (ja) * 2013-04-24 2014-11-17 学校法人加計学園 八面体構造を有するｂ型肝炎ウイルス様粒子結晶
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
WO2022133230A1 (en) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098704A (en) * 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
KR970010787A (ko) * 1995-08-14 1997-03-27 성재갑 B형 간염 바이러스 표면항원과 c형 간염 바이러스 외피 단백질의 융합 단백질 및 이를 포함하는 혼합 백신

Also Published As

Publication number Publication date
WO2001038358A2 (en) 2001-05-31
EP1233783B9 (en) 2006-03-15
DE60018601T4 (de) 2008-05-21
WO2001038358A9 (en) 2002-06-27
DE60018601D1 (de) 2005-04-14
JP4647870B2 (ja) 2011-03-09
CA2392527A1 (en) 2001-05-31
ES2430368T3 (es) 2013-11-20
JP2003514576A (ja) 2003-04-22
EP1233783A2 (en) 2002-08-28
EP1233783B1 (en) 2005-03-09
AU1928201A (en) 2001-06-04
WO2001038358A3 (en) 2002-01-10
CA2392527C (en) 2013-09-10
DE60018601T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
Jegerlehner et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses
Brune et al. Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
Ulrich et al. Core particles of hepatitis B virus as carrier for foreign epitopes
ATE290399T1 (de) Hbv/hcv virus-ohnliche particle
Lee et al. Interaction of the hepatitis B core antigen and the innate immune system
Speidel et al. Priming of cytotoxic T lymphocytes by five heat‐aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses
Tang et al. A modular vaccine development platform based on sortase-mediated site-specific tagging of antigens onto virus-like particles
BR0113307A (pt) Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado
WO2002009645A3 (en) Intercellular transport protein linked to an antigen as a molecular vaccine
CA2405438A1 (en) Hepatitis b core antigen fusion proteins
CY1115010T1 (el) ΕΝΑΣ ΜΟΛΥΣΜΑΤΙΚΟΣ cDNA ΚΛΩΝΟΣ ΤΟΥ ΙΟΥ ΤΟΥ ΧΟΙΡΕΙΟΥ ΑΝΑΠΑΡΑΓΩΓΙΚΟΥ ΚΑΙ ΑΝΑΠΝΕΥΣΤΙΚΟΥ ΣΥΝΔΡΟΜΟΥ ΒΟΡΕΙΟΥ ΑΜΕΡΙΚΗΣ (PRRS) ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ
PL338478A1 (en) Immunological response in respect to hpv antigens induced by compositions comprising a hpv antigen and a shock protein or expression vector capable to express such protein
KR880009130A (ko) 간염 b 바이러스 표면항원 및 이를 함유하는 하이브리드 항원
IE53873B1 (en) Preparation of polypeptides in vertebrate cell culture
Mihailova et al. Recombinant virus-like particles as a carrier of B-and T-cell epitopes of hepatitis C virus (HCV)
KR880701283A (ko) Aids의 원인이 되는 비루스의 당단백질을 암호화하는 비루스 벡터, 백신 및 항체
WO2005021713A8 (en) Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
MY157396A (en) Novel fusion proteins and use thereof for preparing hepatitis c vaccines
Grabherr et al. The baculovirus expression system as a tool for generating diversity by viral surface display
JP2003514576A5 (enExample)
Osamu et al. Purification of hepatitis B virus gene X product synthesized in Escherichia coli and its detection in a human hepatoblastoma cell line producing hepatitis B virus
EP1535628A3 (en) HBV/HCV virus-like particle
Kazaks et al. Stop codon insertion restores the particle formation ability of hepatitis B virus core-hantavirus nucleocapsid protein fusions
Valenzuela et al. Hepatitis-B vaccine: Characterization of hepatitis-B antigen particles produced in yeast.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1233783

Country of ref document: EP